Medicxi’s new €400M fund unites early, late stage investing

In age of megarounds, Medicxi is sticking with its asset-focused approach with its third fund

Medicxi’s newly closed third fund, its largest ever, will depart from the VC’s prior strategy by consolidating early and late stage investing into a single vehicle.

Medicxi III will deploy €400 million ($451.2 million) across all stages of development, from company creation through late-stage clinical assets that have already shown proof of concept. 

It follows the firm’s initial

Read the full 584 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE